Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension
- VernacularTitle:马来酸桂哌齐特注射液对缺血性卒中急性期伴高血压患者血压的影响
- Author:
Huisheng CHEN
1
;
Yi YANG
;
Jun NI
;
Guofang CHEN
;
Yong JI
;
Fei YI
;
Zhuobo ZHANG
;
Jin WU
;
Xueli CAI
;
Bei SHAO
;
Jianfeng WANG
;
Yafang LIU
;
Deqin GENG
;
Xinhui QU
;
Xiaohong LI
;
Yan WEI
;
Shugen HAN
;
Runxiu ZHU
;
Jianping DING
;
Hua LYU
;
Yining HUANG
;
Yonghua HUANG
;
Bo XIAO
;
Tao GONG
;
Xiaofei YU
;
Liying CUI
Author Information
- Keywords: Stroke; Multicenter study; Randomized controlled trial; Blood pressure; Cinepazide maleate; Placebos
- From: Chinese Journal of Internal Medicine 2022;61(8):916-920
- CountryChina
- Language:Chinese
- Abstract: Objective:To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection.Methods:This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke: a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate or control, which were assessed during the treatment period (14 days), and the proportion of the patients with normal blood pressure was analyzed after the treatment period. Furthermore, a subgroup analysis was performed to investigate a possible effect of the history of hypertension on outcomes.Results:This analysis included 809 patients with hypertension. There was no significant difference in patients blood pressure and the proportion of patients with normal blood pressure (60.5% vs. 59.0%, P>0.05) between cinepazide maleate group and control group. Conclusion:Administration of cinepazide maleate injection does not affect the management of clinical blood pressure in patients with AIS.
